New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Pediatric Hodgkin Lymphoma, Version 3.2021.
Pediatric Hodgkin Lymphoma, Version 3.2021. Journal of the National Comprehensive Cancer Network : JNCCN Flerlage, J. E., Hiniker, S. M., Armenian, S., Benya, E. C., Bobbey, A. J., Chang, V., Cooper, S., Coulter, D. W., Cuglievan, B., Hoppe, B. S., Isenalumhe, L., Kelly, K., Kersun, L., Lamble, A. J., Larrier, N. A., Magee, J., Oduro, K., Pacheco, M., Price, A. P., Roberts, K. B., Smith, C. M., Sohani, A. R., Trovillion, E. M., Walling, E., Xavier, A. C., Burns, J. L., Campbell, M. 2021; 19 (6): 733-754Abstract
Hodgkin lymphoma (HL) is a highly curable form of cancer, and current treatment regimens are focused on improving treatment efficacy while decreasing the risk of late effects of treatment. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric HL provide recommendations on the workup, diagnostic evaluation, and treatment of classic HL, including principles of pathology, imaging, staging, systemic therapy, and radiation therapy. This portion of the NCCN Guidelines focuses on the management of pediatric classic HL in the upfront and relapsed/refractory settings.
View details for DOI 10.6004/jnccn.2021.0027
View details for PubMedID 34214968